BiotechTube

azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Maxillary Sinusitis

Conditions

Maxillary Sinusitis

Trial Timeline

Jan 1, 2003 → Feb 1, 2004

NCT ID
NCT00643409

About azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin

azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin is a phase 3 stage product being developed by Pfizer for Maxillary Sinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00643409. Target conditions include Maxillary Sinusitis.

What happened to similar drugs?

2 of 4 similar drugs in Maxillary Sinusitis were approved

Approved (2) Terminated (1) Active (2)
✅Azithromycin + TelithromycinSanofiApproved
✅Avelox (Moxifloxacin, BAY12-8039)BayerApproved
🔄levofloxacinJohnson & JohnsonPhase 3
🔄TelithromycinSanofiPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00643409Phase 3Completed
NCT00644449Phase 3Completed

Competing Products

5 competing products in Maxillary Sinusitis

See all competitors
ProductCompanyStageHype Score
levofloxacinJohnson & JohnsonPhase 3
40
Azithromycin SR + Amoxiclav 1000 mgPfizerPre-clinical
26
TelithromycinSanofiPhase 3
40
Azithromycin + TelithromycinSanofiApproved
35
Avelox (Moxifloxacin, BAY12-8039)BayerApproved
40